Hydrochloric Acid

Hydrochloric Acid

SCHEMBL7932700

CC(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@H](OC(C)=O)[C@@H]1OC(C)=O.Cl

nearest known ligand 0.60

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 known ✓ P00918 6/20 0.47
PRKCA known ✓ P17252 1/20 0.46
LMNA P02545 3/20 0.52
THRB P10828 2/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
HIF1A Q16665 1/20 0.52
ALDH1A1 P00352 2/20 0.52
TP53 P04637 1/20 0.52
MAPT P10636 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
MTOR P42345 1/20 0.50
MDM2 Q00987 1/20 0.50
NCOA1 Q15788 1/20 0.50
NCOA3 Q9Y6Q9 1/20 0.50
CA1 P00915 6/20 0.47
CA9 Q16790 6/20 0.47
CA12 O43570 5/20 0.47
CA14 Q9ULX7 5/20 0.47
AKT1 P31749 1/20 0.46
PTK2 Q05397 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4977129 1.00 LMNA (0.52) LMNATHRBSMN1; SMN2HIF1AALDH1A1
Hydrochloric Acid SCHEMBL4977138 1.00 LMNA (0.52) LMNATHRBSMN1; SMN2HIF1AALDH1A1
SCHEMBL2238447 0.99 LMNA (0.53) LMNATHRBSMN1; SMN2HIF1AALDH1A1
SCHEMBL10813233 0.99 LMNA (0.53) LMNATHRBSMN1; SMN2HIF1AALDH1A1
SCHEMBL6536598 0.99 LMNA (0.53) LMNATHRBSMN1; SMN2HIF1AALDH1A1
SCHEMBL9068649 0.99 LMNA (0.53) LMNATHRBSMN1; SMN2HIF1AALDH1A1
SCHEMBL10431963 0.92 LMNA (0.50) LMNATHRBSMN1; SMN2HIF1AALDH1A1
SCHEMBL11793030 0.91 LMNA (0.57) LMNATHRBSMN1; SMN2HIF1AALDH1A1
SCHEMBL10589686 0.90 LMNA (0.48) LMNATHRBSMN1; SMN2HIF1AALDH1A1
SCHEMBL10887173 0.90 LMNA (0.48) LMNATHRBSMN1; SMN2HIF1AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12054768-B2 Methods for detecting agglutination and compositions for use in practicing the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-08-06 US disclosed
EP-4123031-A1 METHODS FOR DETECTING AGGLUTINATION AND COMPOSITIONS FOR USE IN PRACTICING THE SAME The Regents of The University of California (US) 2023-01-25 EP disclosed
EP-3283638-B1 METHODS FOR DETECTING AGGLUTINATION AND USE OF KITS IN PRACTICING THE SAME UNIV CALIFORNIA (US) 2022-06-08 EP disclosed
US-20210403978-A1 METHODS FOR DETECTING AGGLUTINATION AND COMPOSITIONS FOR USE IN PRACTICING THE SAME THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2021-12-30 US disclosed
US-11149296-B2 Methods for detecting agglutination and compositions for use in practicing the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-10-19 US disclosed
US-10584363-B2 Methods of producing and using single-stranded deoxyribonucleic acids and compositions for use in practicing the same TAKARA BIO USA, INC. (US) 2020-03-10 US disclosed
US-20180100181-A1 METHODS FOR DETECTING AGGLUTINATION AND COMPOSITIONS FOR USE IN PRACTICING THE SAME THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2018-04-12 US disclosed
US-20170349927-A1 METHODS OF PRODUCING AND USING SINGLE-STRANDED DEOXYRIBONUCLEIC ACIDS AND COMPOSITIONS FOR USE IN PRACTICING THE SAME TAKARA BIO USA, INC. 2017-12-07 US disclosed
US-6316426-B1 NUCLEOSIDE DERIVATIVE FOR DIABETES, HEART DISEASE, CEREBROVASCULAR DISORDERS, PARKINSON'S DISEASE, INFANT RESPIRATORY DISTRESS SYNDROME AND FOR ENHANCEMENT OF PHOSPHOLIPID BIOSYNTHESIS PRO-NEURON, INC. 2001-11-13 US disclosed
US-6274563-B1 ADMINISTERING AS ANTIDIABETIC AGENT PRO-NEURON, INC. 2001-08-14 US disclosed
US-5583117-A CARDIOVASCULAR, NERVOUS SYSTEM DISORDERS; DIABETES PRO-NEURON, INC. (US) 1996-12-10 US disclosed
US-5470838-A Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine PRO-NEURON, INC. (US) 1995-11-28 US disclosed
EP-0339075-B1 ACYLATED URIDINE AND CYTIDINE AND USES THEREOF PRO-NEURON, INC. (US) 1993-08-18 EP disclosed
EP-0339075-A4 ACYLATED URIDINE AND CYTIDINE AND USES THEREOF. PRO NEURON INC (US) 1990-04-10 EP disclosed
EP-0339075-A1 ACYLATED URIDINE AND CYTIDINE AND USES THEREOF PRO-NEURON, INC. (US) 1989-11-02 EP disclosed
WO-1989003837-A1 ACYLATED URIDINE AND CYTIDINE AND USES THEREOF PRO-NEURON, INC. (US) 1989-05-05 WO disclosed